2017 Press Releases

RSS Feeds RSS
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
08/16/17Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney CancerPrinter Friendly Version
08/02/17Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/01/17Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 CongressPrinter Friendly Version
07/20/17Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for CobimetinibPrinter Friendly Version
07/17/17Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017Printer Friendly Version
07/10/17Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPrinter Friendly Version
06/29/17Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of IndebtednessPrinter Friendly Version
06/19/17Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell CarcinomaPrinter Friendly Version
06/12/17Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid TumorsPrinter Friendly Version
06/08/17Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13Printer Friendly Version
05/03/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
05/01/17Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
04/24/17Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3Printer Friendly Version
04/18/17Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017Printer Friendly Version
04/04/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
03/29/17Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term LoanPrinter Friendly Version
03/27/17Exelixis to Present at the Needham & Company Healthcare Conference on April 4Printer Friendly Version
03/06/17Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular CarcinomaPrinter Friendly Version
03/01/17Exelixis Announces Webcasts of Investor Conference Presentations in MarchPrinter Friendly Version
02/28/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
02/27/17Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid TumorsPrinter Friendly Version
02/27/17Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell CarcinomaPrinter Friendly Version
02/27/17Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/17/17Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary TumorsPrinter Friendly Version
02/07/17Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15Printer Friendly Version
02/02/17Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017Printer Friendly Version
01/31/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
01/30/17Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in JapanPrinter Friendly Version
01/09/17Update on Dispute between Exelixis and Genentech, a Member of the Roche GroupPrinter Friendly Version
01/03/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version